Document Detail

Increased serum apolipoprotein(a) in patients with chronic renal failure treated with continuous ambulatory peritoneal dialysis.
MedLine Citation:
PMID:  1596303     Owner:  NLM     Status:  MEDLINE    
Patients with end-stage renal failure (ESRF) on renal replacement therapy are at significantly increased risk of cardiovascular disease. To determine whether altered concentrations of apolipoprotein(a) (apo(a)), the plasminogen-like protein moiety of the atherogenic particle lipoprotein(a), contributed to this increased risk, apo(a) concentrations were measured in 48 non-diabetic patients with ESRF treated by continuous ambulatory peritoneal dialysis (CAPD) therapy and compared with 65 controls. Apo(a) concentration was increased in CAPD patients compared to controls (geometric mean 419 units/l versus 137 units/l; ratio of means 3.06 (95% CI 1.95-4.80). We conclude that CAPD patients have increased apo(a) concentrations which may contribute to their increased risk of cardiovascular disease.
B G Murphy; P McNamee; E Duly; W Henry; P Archbold; T Trinick
Related Documents :
1154213 - Gardner's syndrome.
1188573 - Total proctocolectomy without the lithotomy position.
6120403 - Diagnostic cardiac premonitory signs and symptoms of red scorpion sting.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Atherosclerosis     Volume:  93     ISSN:  0021-9150     ISO Abbreviation:  Atherosclerosis     Publication Date:  1992 Mar 
Date Detail:
Created Date:  1992-07-01     Completed Date:  1992-07-01     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0242543     Medline TA:  Atherosclerosis     Country:  NETHERLANDS    
Other Details:
Languages:  eng     Pagination:  53-7     Citation Subset:  IM    
Regional Nephrology Unit, Belfast City Hospital, Northern Ireland.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Apolipoproteins / blood*
Cholesterol / blood
Kidney Failure, Chronic / blood*,  therapy
Peritoneal Dialysis, Continuous Ambulatory*
Triglycerides / blood
Reg. No./Substance:
0/Apolipoproteins; 0/Lipoprotein(a); 0/Triglycerides; 57-88-5/Cholesterol; EC 3.4.21.-/Apoprotein(a)

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Formation of intimal cushions in the ductus arteriosus as a model for vascular intimal thickening. A...
Next Document:  Is fat restriction needed with HMGCoA reductase inhibitor treatment?